Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001607062-19-000354
Filing Date
2019-08-30
Accepted
2019-08-30 13:52:02
Documents
56
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-K zander063019form10k.htm 10-K 1004109
2 EXHIBIT 31.1 ex31_1.htm EX-31.1 7357
3 EXHIBIT 31.2 ex31_2.htm EX-31.2 7441
4 EXHIBIT 32.1 ex32_1.htm EX-32.1 3939
5 EXHIBIT 32.2 ex32_2.htm EX-32.2 4385
  Complete submission text file 0001607062-19-000354.txt   3832499

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE zander-20190630.xml EX-101.INS 714448
7 XBRL SCHEMA FILE zander-20190630.xsd EX-101.SCH 40759
8 XBRL CALCULATION FILE zander-20190630_cal.xml EX-101.CAL 34363
9 XBRL DEFINITION FILE zander-20190630_def.xml EX-101.DEF 154857
10 XBRL LABEL FILE zander-20190630_lab.xml EX-101.LAB 198198
11 XBRL PRESENTATION FILE zander-20190630_pre.xml EX-101.PRE 213992
Mailing Address 4700 SPRING ST LA MESA CA 91942-0274
Business Address 4700 SPRING ST LA MESA CA 91942-0274 6192279192
Zander Therapeutics, Inc (Filer) CIK: 0001718644 (see all company filings)

EIN.: 474321638 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 10-K | Act: 34 | File No.: 333-220790 | Film No.: 191069020
SIC: 2834 Pharmaceutical Preparations